指南与共识血脂与心血管预防

2026与2018 ACC/AHA多学会血脂异常指南对美国成人临床管理的影响

Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults.
指南 / 共识 · J Am Coll Cardiol · 2026-07-29

研究基于2011-2020年NHANES四个调查周期数据,量化2026版血脂异常指南与2018版指南对美国成人降脂治疗启动资格及达标情况的人群层面影响。已接受降脂治疗者中多数LDL-C未达新指南目标。

要点

  • 已接受降脂治疗且为Class 1适应证者中79.0% LDL-C未达标,ASCVD患者91.1% LDL-C≥55 mg/dL。

核心结论

  • 与2018版指南相比,2026版ACC/AHA多学会血脂异常指南通过将推荐扩展至30年高风险成人,大幅扩大了应考虑他汀治疗的人群比例。
  • 已接受治疗者中绝大多数LDL-C仍高于新指南目标,全国层面需显著转变他汀启动和治疗强化模式。

研究设计与样本

  • 研究使用2011-2020年NHANES四个调查周期数据,估算美国20岁及以上成人中符合2026版与2018版指南降脂治疗启动条件的比例和人数,以及达到2026版治疗目标的比例。

关键数值与推荐

  • 2026版指南新增推荐:30-59岁成人10年ASCVD风险<3%但30年ASCVD风险≥10%时考虑他汀治疗。
  • 2026版指南下无ASCVD、LDL-C≥70 mg/dL未治疗成人中40.5%符合降脂治疗启动条件,2018版为25.7%。
  • 已治疗Class 1适应证成人中79.0% LDL-C未达标,ASCVD患者中91.1% LDL-C≥55 mg/dL、74.5% LDL-C≥70 mg/dL。

临床怎么用

  • 心内科医生应关注30-59岁成人长期ASCVD风险评估,对10年风险低但30年风险≥10%者考虑启动他汀。
  • 对已接受降脂治疗者应评估LDL-C是否达到2026版指南目标,多数患者需强化治疗。
  • 全国层面实现指南目标需要显著增加他汀启动和治疗强化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American College of Cardiology and American Heart Association recently updated their guidelines for dyslipidemia, which included recommending new risk calculators and thresholds, treatment targets, and treatment recommendations based on long-term risk. OBJECTIVES: The purpose of this study was to quantify the population-level implications of the 2026 Dyslipidemia Guideline. METHODS: Using data across 4 survey cycles from the 2011-2020 NHANES (National Health and Nutrition Examination Survey), we estimated the proportion and number of U.S. adults aged 20 years or older who were eligible for initiation of lipid-lowering therapy (LLT) under the 2026 vs 2018 guideline recommendations and the proportion meeting their 2026 treatment targets RESULTS: Among U.S. adults ≥20 years of age without atherosclerotic cardiovascular disease (ASCVD), with a low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL, and not on LLT (n = 165.4 million), 40.5% were eligible per the 2026 guideline vs 25.7% per the 2018 guideline, representing an additional 24.5 million adults. The largest contributor to the increase was the recommendation to consider statins in adults aged 30 to 59 years with a 30-year ASCVD risk ≥10% despite a 10-year risk <3%, based on which 15.6 million more adults would be eligible. In this age group, nearly twice as many qualify based on a 30-year ASCVD ≥10% vs 10-year ASCVD risk ≥3% (15.6 million vs 7.9 million). Among 39.1 million adults receiving LLT for a Class 1 indication, most (79.0%) had LDL-C above goal, including 91.1% of adults with ASCVD having LDL-C ≥55 mg/dL and 74.5% with LDL-C ≥70 mg/dL. CONCLUSIONS: Compared with the 2018 guideline, the 2026 American College of Cardiology/American Heart Association Multisociety Dyslipidemia Guideline substantially expanded the proportion of U.S. adults for whom statin therapy should be considered by extending recommendations to adults at high 30-year risk. Among those already on treatment, the vast majority remain above new guideline goals. Significant population-level shifts in statin initiation and therapy intensification will be needed to reach guideline goals at a national level.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sayed A, Peterson ED, Navar AM, et al. Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults. J Am Coll Cardiol. 2026. PMID: 42584382. doi:10.1016/j.jacc.2026.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。